Chemotherapy and pregnancy.
Leslie
Kimberly K
KK
Department of Obstetrics and Gynecology, The University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87131, USA. kleslie@salud.unm.edu
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology / Q000627:therapeutic use; D003561:Cytarabine / Q000494:pharmacology; D003630:Daunorubicin / Q000494:pharmacology / Q000627:therapeutic use; D004317:Doxorubicin / Q000494:pharmacology / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005047:Etoposide / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005333:Fetus / Q000187:drug effects*; D006801:Humans; D019384:Nucleic Acid Synthesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D017239:Paclitaxel / Q000494:pharmacology / Q000627:therapeutic use; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D019772:Topotecan / Q000494:pharmacology / Q000627:therapeutic use; D000068878:Trastuzumab; D014747:Vinblastine / Q000494:pharmacology / Q000627:therapeutic use; D014750:Vincristine / Q000494:pharmacology / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D004791:Enzyme Inhibitors; D019384:Nucleic Acid Synthesis Inhibitors; D003561:Cytarabine; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; D019772:Topotecan; D004317:Doxorubicin; D000068878:Trastuzumab; D017239:Paclitaxel; D003630:Daunorubicin